C12N 2760/18641
Use of virus, viral particle or viral elements as a vector
C12N2760/18641 (Use of virus, viral particle or viral elements as a vector) appears on 40 US grants and 57 published applications in this corpus.
Search patents in C12N- Granted patents
- 40
- Published applications
- 57
- Assignees
- 39
- Inventors
- 81
- Latest grant
- 2 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 1 | 1 |
| 2003 | 0 | 4 |
| 2004 | 2 | 5 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 5 | 2 |
| 2008 | 3 | 2 |
| 2009 | 1 | 3 |
| 2010 | 5 | 4 |
| 2011 | 2 | 2 |
| 2012 | 0 | 2 |
| 2013 | 1 | 1 |
| 2014 | 2 | 2 |
| 2015 | 1 | 1 |
| 2016 | 0 | 2 |
| 2017 | 3 | 1 |
| 2018 | 1 | 4 |
| 2019 | 1 | 0 |
| 2020 | 2 | 4 |
| 2021 | 1 | 2 |
| 2022 | 3 | 3 |
| 2023 | 1 | 2 |
| 2024 | 3 | 4 |
| 2025 | 0 | 3 |
| 2026 | 2 | 1 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/18643Viral genome or elements thereof as genetic vectorIndexing code39
- C12N 2760/18645Special targeting system for viral vectorsIndexing code4
- C12N 2760/18642Virus or viral particle as vehicleIndexing code0
- C12N 2760/18644Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
Recent patents
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/PIV3 F protein and uses thereof2 Jun 2026US 12,643,925 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Method for producing induced pluripotent stem cells20 Jan 2026US 12,529,035 B1National University Corporation Kobe University
- Temperature-based transient delivery of nucleic acids and proteins to cells and tissues13 Aug 2024US 12,060,568 B2Elixirgen Therapeutics, Inc.
- Recombinant human parainfluenza virus type 1 expressing a chimeric RSV/HPIV1 f protein and uses thereof25 Jun 2024US 12,018,051 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use7 May 2024US 11,975,063 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Programmable miRNA-Dependent Gene Expression1 Oct 2026US 2026/0295089 A1New York University
- Bovine viral diarrhea virus immunogenic compositions and methods of use thereof23 Oct 2025US 2025/0325645 A1Kansas State University Research Foundation
- A SARS-COV-2 Human Parainfluenza Virus Type 3-Vectored Vaccine27 Feb 2025US 2025/0064919 A1Board of Regents, The University of Texas System
- Temperature-based transient delivery of nucleic acids and proteins to cells and tissues23 Jan 2025US 2025/0027111 A1Elixirgen Therapeutics, Inc.
- Human metapneumovirus viral vector-based vaccines19 Dec 2024US 2024/0415952 A1Sanofi Pasteur Limited
Most cited
By later US patents
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences30US 7,449,324 B2MedImmune, LLC · 2008
- Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences28US 7,208,161 B1The United States of America, as represented by the Secretary, Department of Health and Human Services · 2007
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences27US 8,841,433 B2ViroNovative BV · 2014
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences22US 9,567,653 B2Erasmus University Medical Center Rotterdam · 2017
- Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA and use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens19US 7,704,509 B2United States of America · 2010